Caribou Biosciences (CRBU) Receivables - Net (2020 - 2026)
Caribou Biosciences (CRBU) reported Receivables - Net of $227000.0 for Q1 2026, up 157.95% year-over-year from $88000.0 in Q1 2025, and up 228.99% quarter-over-quarter from $69000.0 in Q4 2025.
Caribou Biosciences (CRBU) Receivables - Net (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of Receivables - Net data on file, last reported at $227000.0 in Q1 2026.
- Receivables - Net for Q1 2026 came in at $227000.0, up 157.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $227000.0 (up 157.95% YoY), and the FY2025 annual result was $69000.0, down 73.96% from the prior year.
- Receivables - Net rose to $227000.0 in Q1 2026 per CRBU's latest filing, from $69000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $1.5 million in Q1 2023 and troughed at $69000.0 in Q4 2025.
- A 5-year average of $432647.1 and a median of $242000.0 in 2025 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2022 and 2025: Receivables - Net surged 26100.0% in 2022, then slumped 90.4% in 2025.
- A 5-year view of Receivables - Net shows it stood at $202000.0 in 2022, then slipped by 26.73% to $148000.0 in 2023, then soared by 79.05% to $265000.0 in 2024, then slumped by 73.96% to $69000.0 in 2025, then surged by 228.99% to $227000.0 in 2026.
- Business Quant data shows CRBU's Receivables - Net at $227000.0 in Q1 2026, $69000.0 in Q4 2025, and $242000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Sep 30, 2024 | 184,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Mar 31, 2024 | 917,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |